EQUITY RESEARCH MEMO

Apollo Biologics

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)65/100

Apollo Biologics is a specialized consulting firm based in San Diego, California, focused on biologics drug development. Founded in 2015, the company offers expert services in bioanalytical assay development, CMC (Chemistry, Manufacturing, and Controls), regulatory strategy, and due diligence. By leveraging deep technical and regulatory expertise, Apollo supports a diverse client base ranging from large pharmaceutical companies to small biotechnology firms. The firm's position in the rapidly growing biologics market, combined with its proven track record since inception, makes it a reliable partner for drug developers navigating complex regulatory landscapes. As the biologics sector continues to expand, Apollo is well-placed to benefit from increased outsourcing of specialized development services.

Upcoming Catalysts (preview)

  • Q2 2026Expansion into gene therapy and cell therapy consulting70% success
  • H2 2026Strategic partnership with a major CRO or CDMO60% success
  • H1 2027New regulatory guidance on biosimilars boosting consulting demand55% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)